The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...

CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments. The insulin product, which is ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...

German biosimilars specialist Formycon (FWB: FYB) has won US approval for Nufymco (ranibizumab), an interchangeable ...

Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...

The U.S. FDA on Wednesday issued draft guidance that aims to accelerate the process for getting biosimilar drugs -- essentially generic versions of pricey biologic-based medicines -- to consumers. The ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...